22 February 2021 – Spain participates in European variant vaccine project

Type of Intervention: Specific Action
Sectors Involved: Health, Research and Development
Level of Jurisdiction: National
Lead People/Agency: Ministry of Science and Innovation and the the Carlos III Health Institute

Overview: Title: Spain to take part, through the Carlos III Health Institute, in European project to research variants of SARS-CoV-2 and the development of vaccines

Overview: The European Commission has just launched a new initiative to improve research and the handling of potential new variants of the coronavirus SARS-CoV-2 that may emerge

The aim of the project, entitled HERA Incubator: anticipating together the threat of COVID-19 variants, is to promote actions to detect, analyse and evaluate variants; speed up the development and approval of vaccines, and facilitate the performance of clinical trials with prototypes of vaccines that include the potential influence of variants of the virus.
As part of this last objective, the HERA Incubator includes the VACCELERATE project, in which Spain is participating through the Carlos III Health Institute (Spanish acronym: ISCIII), which will receive funding of almost 1 million euros (around 8% of the total of 12 million euros). VACCELERATE will include the participation of 26 institutions from 16 EU Member States, plus the collaboration of five associate countries.

Full details here: https://www.lamoncloa.gob.es/lang/en/gobierno/news/Paginas/2021/20210222isciii-vaccines.aspx

Other links: 1
Type of Justification: Scientific Evidence (e.g. academic paper, report)
Source of Evidence or Justification: National – academic, International – academic